Zidovudine-based lytic-inducing chemotherapy for Epstein–Barr virus-related lymphomas

References

• Shibata D, Weiss LM, Hernandez AM, et al. Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. Blood 1993;81:2102–2109.
   PubMed Web of Science ®Google Scholar
• Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997;89:1413–1420.
   PubMed Web of Science ®Google Scholar
• Carbone A, Cesarman E, Spina M, et al. HIV-associated lymphomas and gamma-herpesviruses. Blood 2009;113:1213–1224.
   PubMed Web of Science ®Google Scholar
• Cesarman E, Mesri EA. Pathogenesis of viral lymphomas. Cancer Treat Res 2006;131:49–88.
   PubMedGoogle Scholar
• Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004;350:1328–1337.
   PubMed Web of Science ®Google Scholar
• Kulwichit W, Edwards RH, Davenport EM, et al. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 1998;95:11963–11968.
   PubMed Web of Science ®Google Scholar
• Mentzer SJ, Fingeroth J, Reilly JJ, et al. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. Blood Cells Mol Dis 1998;24:114–123.
   PubMed Web of Science ®Google Scholar
• Di Renzo L, Avila-Carino J, Klein E. Induction of the lytic viral cycle in Epstein Barr virus carrying Burkitt lymphoma lines is accompanied by increased expression of major histocompatibility complex molecules. Immunol Lett 1993;38:207–214.
   PubMed Web of Science ®Google Scholar
• Moore SM, Cannon JS, Tanhehco YC, et al. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother 2001;45:2082–2091.
   PubMed Web of Science ®Google Scholar
• Feng WH, Hong G, Delecluse HJ, et al. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol 2004;78: 1893–1902.
   PubMed Web of Science ®Google Scholar
• Gustafson EA, Chillemi AC, Sage DR, et al. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase. Antimicrob Agents Chemother 1998;42:2923–2931.
   PubMed Web of Science ®Google Scholar
• Kurokawa M, Ghosh SK, Ramos JC, et al. Azidothymidine inhibits NF-kappaB and induces Epstein-Barr virus gene expression in Burkitt lymphoma. Blood 2005;106:235–240.
   PubMed Web of Science ®Google Scholar
• Ramos JC, Sin SH, Staudt MR, et al. Nuclear factor kappa B pathway associated biomarkers in AIDS defining malignancies. Int J Cancer 2012;130:2728–2733.
   PubMed Web of Science ®Google Scholar
• Tosi P, Calabresi P, Goulette FA, et al. Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo. Cancer Res 1992;52:4069–4073.
   PubMed Web of Science ®Google Scholar
• Lima RT, Seca H, Bras S, et al. Treatment of Akata EBV-positive cells with doxorubicin causes more EBV reactivation than treatment with etoposide. Chemotherapy 2011;57:195–203.
   PubMed Web of Science ®Google Scholar
• Wynn HE, Brundage RC, Fletcher CV. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 2002;16:595–609.
   PubMed Web of Science ®Google Scholar
• Sarker D, Thirlwell C, Nelson M, et al. Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma. AIDS 2003;17:861–865.
   PubMed Web of Science ®Google Scholar
• Tosi P, Gherlinzoni F, Mazza P, et al. 3’-Azido 3’-deoxythymidine + methotrexate as a novel antineoplastic combination in the treatment of human immunodeficiency virus-related non-Hodgkin's lymphomas. Blood 1997;89:419–425.
   PubMed Web of Science ®Google Scholar
• Raez L, Cabral L, Cai JP, et al. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res Hum Retroviruses 1999;15:713–719.
   PubMed Web of Science ®Google Scholar
• Ghosh SK, Wood C, Boise LH, et al. Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. Blood 2003; 101:2321–2327.
   PubMed Web of Science ®Google Scholar
• Lee RK, Cai JP, Deyev VV, et al. Azidothymidine and interferon-alpha induce apoptosis in herpesvirus-associated lymphomas. Cancer Res 1999;59:5514–5520.
   PubMed Web of Science ®Google Scholar
• Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood 2011;117:6977–6986.
   PubMed Web of Science ®Google Scholar
• Roychowdhury S, Peng R, Baiocchi RA, et al. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res 2003;63:965–971.
   PubMed Web of Science ®Google Scholar
• Little RF. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003; 101:4653–4659.
   PubMed Web of Science ®Google Scholar
• Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002;94:1492–1499.
   PubMed Web of Science ®Google Scholar
• Toomey NL, Deyev VV, Wood C, et al. Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma. Oncogene 2001;20:7029–7040.
   PubMed Web of Science ®Google Scholar
• Ryan JL, Fan H, Glaser SL, et al. Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. J Mol Diagn 2004;6:378–385.
   PubMed Web of Science ®Google Scholar
• Tang W, Harmon P, Gulley ML, et al. Viral response to chemotherapy in endemic burkitt lymphoma. Clin Cancer Res 2010;16:2055–2064.
   PubMed Web of Science ®Google Scholar
• Navarro JT, Lloveras N, Ribera JM, et al. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica 2005;90:704–706.
   PubMed Web of Science ®Google Scholar
• Bayraktar S, Bayraktar UD, Ramos JC, et al. Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol 2011;101:257–265.
   PubMed Web of Science ®Google Scholar
• Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: Lessons learned from 112 published cases. Am J Hematol 2008;83:804–809.
   PubMed Web of Science ®Google Scholar
• Weiss R, Mitrou P, Arasteh K, et al. Acquired immunodeficiency syndrome-related lymphoma: Simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival. Cancer 2006;106:1560–1568.
   PubMed Web of Science ®Google Scholar
• MacMahon EM, Glass JD, Hayward SD, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991;338:969–973.
   PubMed Web of Science ®Google Scholar
• Baumgartner JE, Rachlin JR, Beckstead JH, et al. Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg 1990;73:206–211.
   PubMed Web of Science ®Google Scholar
• Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS 2003;17:1787–1793.
   PubMed Web of Science ®Google Scholar
• Kreisl T, Panageas KS, Elkin EB, et al. Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central nervous system lymphoma. Leuk Lymphoma 2008;49:1710–1716.
   PubMed Web of Science ®Google Scholar
• Aboulafia DM, Ratner L, Miles SA, et al. Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma 2006;6:399–402.
   PubMedGoogle Scholar
• Shewach DS, Lawrence TS. Antimetabolite radiosensitizers. J Clin Oncol 2007;25:4043–4050.
   PubMed Web of Science ®Google Scholar
• Cannon JS, Hamzeh F, Moore S, et al. Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J Virol 1999;73:4786–4793.
   PubMed Web of Science ®Google Scholar
• Martin JC, Dvorak CA, Smee DF, et al. 9-[(1,3-Dihydroxy- 2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. J Med Chem 1983;26:759–761.
   PubMed Web of Science ®Google Scholar
• Staudt MR, Kanan Y, Jeong JH, et al. The tumor microenvironment controls primary effusion lymphoma growth in vivo. Cancer Res 2004;64:4790–4799.
   PubMed Web of Science ®Google Scholar
• Meng Q, Hagemeier SR, Fingeroth JD, et al. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production. J Virol 2010;84:4534–4542.
   PubMed Web of Science ®Google Scholar
• Westphal EM, Blackstock W, Feng W, et al. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res 2000;60:5781–5788.
   PubMed Web of Science ®Google Scholar
• Ghosh SK, Perrine SP, Williams RM, et al. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood 2012;119:1008–1017.
   PubMed Web of Science ®Google Scholar
• Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007;109:2571–2578.
   PubMed Web of Science ®Google Scholar